[Federal Register Volume 71, Number 26 (Wednesday, February 8, 2006)]
[Notices]
[Pages 6515-6516]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-1651]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Aminoflavone Compounds as 
Anti-Cancer Agents

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive patent license to practice the inventions embodied in the
    (1) U.S. Provisional Patent Application 60/195,507, filed April 6, 
2000, entitled ``Aminoflavone Compounds, Compositions, and

[[Page 6516]]

Methods of Use Thereof'' and all related foreign patents/patent 
applications (HHS Ref. No. E-279-1999/0);
    (2) U.S. Patent Application 08/014,696, filed February 8, 1993, 
entitled ``5-Aminoflavone Derivatives'' and all related foreign 
patents/patent applications (HHS Ref. No. E-296-2005/1);
    (3) PCT Patent Application PCT/US96/00181, filed August 10, 1994, 
entitled ``5-Aminoflavone Derivatives, Their Preparation and Their Use 
as Antibacterial, Anti-estrogenic and/or Antitumor Agent'' and all 
related foreign patents/patent applications (HHS Ref. No. E-295-2005/
0), with the exception of the JP patent application JP204356/93, filed 
on August 18, 1993;

to Tigris Pharmaceuticals, Inc. located in New York, NY. The patent 
rights in these inventions have been assigned to the United States of 
America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to human pharmaceutical uses of 
aminoflavone compounds as anti-cancer agents.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before April 10, 
2006 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comments and 
other materials relating to the contemplated exclusive license should 
be directed to: George G. Pipia, PhD., Technology Licensing Specialist, 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: 
(301) 435-5560; Facsimile: (301) 402-0220; E-mail: [email protected].

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be 
royalty bearing and will comply with the terms and conditions of 35 
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be 
granted unless within sixty (60) days from the date of this published 
notice, the NIH receives written evidence and argument that establish 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Description of the Technology

    E-279-1999/0: This invention is related to aminoflavone compounds 
with pharmaceutically acceptable properties, claiming pharmaceutical 
compositions and a method of inhibiting tumor growth. The invention 
improves the pharmaceutical property of aminoflavone compounds. The 
present invention addresses these problems by providing a method of 
producing water-soluble analogues of water-insoluble drugs. In 
particular, the present invention describes novel analogues derived 
from 5-aminoflavone (TK2339) compounds. These derivatives have shown 
good differential activity in the NCI 60-cell line in vitro cancer drug 
screen with potent and selective cytotoxicity against CAKI-1 and A498 
renal, MCF-7 breast, and OVCAR-5 ovarian carcinoma cell lines. In 
addition, these derivatives have shown in vivo activity against CAKI-1 
and A498 renal carcinoma xenographs.
    The novel compounds display improved solubility in aqueous 
solutions over the parent compounds (see below) without sacrificing 
potent antitumor activity. Since these compounds possess very favorable 
pharmaceutical properties, they have greater potential to be useful in 
the treatment of human cancers. The claims of the issued patent or 
pending patent applications of this patent family are directed to 
compositions comprising aminoflavone derivatives and to methods of 
their use.
    E-296-2005/0 and E-296-2005/1: These two inventions describe 5-
aminoflavone derivatives, having antibacterial, anti-estrogenic and 
anti-cancer activity. These inventions constitute earlier, parent 5-
aminoflavone compounds, which have inferior solubility in aqueous 
solutions compared to new compounds outlined in E-279-1999/0 
technology.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: January 30, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E6-1651 Filed 2-7-06; 8:45 am]
BILLING CODE 4140-01-P